Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced that a Senhance® Surgical System has been sold to the Company’s distribution partner in Germany focused on Eastern Europe and the Commonwealth of Independent States (CIS) region. The Senhance System will be placed at an end user oncology focused hospital.
“We are very excited about the traction our distribution partner has been able to develop and maintain in this part of the world during what continues to be a turbulent period in time,” said Anthony Fernando, Asensus Surgical President and CEO. “We are especially excited to see hospitals adopt Senhance and use their own capital to do so. This financial commitment demonstrates the Senhance System’s clinical relevance and the value it can deliver.”
Asensus Surgical’s technology platform, Senhance Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning. Senhance goes beyond the typical surgical robotic systems, providing surgical assurance through haptic feedback, eye-tracking camera control, and 3D visualization, and is the first platform to offer 3mm instruments (the smallest instrument available in the world on a robotic surgical platform). The Senhance Surgical System is powered by the Intelligent Surgical Unit™ (ISU™). The ISU enables machine vision-driven control of the camera for a surgeon by responding to commands and recognizing objects and locations in the surgical field, and allows a surgeon to change the visualized field of view using the movement of their instruments.
